Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab versus certolizumab pegol in adults with active ankylosing spondylitis
NL-OMON48835Phase 2Active, not recruiting
- Sponsor
- UCB
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ankylosing spondylitis (AS) comparing Bimekizumab with Cimzia (2 arms). Primary endpoint: Change from baseline in Ankylosing Spondylitis Disease Activity Score. Started Jan 2019; status: active, not recruiting.
02
Drugs
bimekizumabcertolizumab pegol
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NL-OMON48835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48835.